Targeting IGF-1R: At a crossroad

Oncology

Volumn 25, Issue 6, 2011, Pages

  Lee, Adrian V ^a   Yee, Douglas ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIGITUMUMAB; GANITUMAB; INSULIN RECEPTOR; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

ACCURACY; ARTICLE; BREAST CANCER; CANCER REGRESSION; CARCINOGENESIS; CELL PROLIFERATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; EWING SARCOMA; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PREDICTIVE VALUE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

EID: 79956340194     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Rubini M, Hongo A, DAmbrosio C, Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res. 1997;230:284-92.
2. Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2010.
3. Huang F, Greer A, Hurlburt W, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009;69:161-70.
4. Pitts TM, Tan AC, Kulikowski GN, et al. Development of an integrated genomic classifier for a nove agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res. 2010;16:3193-204.
5. Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep. 2010;10:93-100.
6. Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009;69:2443-52.
7. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Inaugural Article: Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A. 2010;107:10781-8.
8. Novosyadlyy R, Lann DE, Vijayakumar A, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 2010;70:741-51.
9. Zeng X, Sachdev D, Zhang H, et al. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res. 2009;15:2840-9.
10. Stiles CD, Capone GT, Scher CD, et al. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci U S A. 1979;76:1279-83.
11. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:2055-63.
12. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19:3278-88.